To determine whether C1q has a role in synapse elimination, the authors examined mice deficient in C1q (C1qa-knockout mice), in which the complement cascade cannot be activated. Defects in synapse ...

A biologic medicine, Ultomiris (ravulizumab) works by inhibiting the complement system, which is thought to play a role in the severe pneumonia that can occur in patients with serious SARS-CoV-2 ...

PNH is an ultra-rare and severe blood disorder characterised by the destruction of red blood cells, thought to be caused by an autoimmune reaction involving the complement system. Ultomiris ...

Ultomiris belongs to a class of medicines called monoclonal antibodies, that attach to a specific target in the body. Ravulizumab rch has been designed to attach to the C5 complement protein ...

Ultomiris serves as a treatment for these autoimmune conditions like Paroxysmal Nocturnal Hemoglobinuria PNH and Atypical Hemolytic Uremic Syndrome aHUS by inhibiting complement protein C5 ...